Article

Managing Cancer Cost Resource Guide

View the webcast here.

Download PDF

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Image credit: viperagp | stock.adobe.com
Image credit: kitsawet | stock.adobe.com
1 expert in this video
1 expert in this video
1 KOL is featured in this series.
Related Content
Coronary artery plaque
July 4th 2025

Elevated Remnant Cholesterol, Lp-PLA2 Linked to Heightened Risk of Composite Adverse Events

Luke Halpern, Assistant Editor
An Overview of Intravenous Iron in Heart Failure and the FAIR-HF2 Trial
July 1st 2025

An Overview of Intravenous Iron in Heart Failure and the FAIR-HF2 Trial

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP Aislinn Antrim, Managing Editor
Humira (adalimumab), reference product to Hadlima, Hyrimoz -- Image credit: Boris | stock.adobe.com
July 4th 2025

Real-World Data Shows Similar Clinical Outcomes in Patients Receiving Biosimilars Following Switch From Reference Product

Gillian McGovern, Associate Editor
Pharmacy Times, Pharmacy Focus Oncology Edition
June 27th 2025

Allen's Story: The Promising Potential of Intratumoral Immunotherapy

Alexandra Gerlach, Associate Editor
Adjusting Asthma Management After Achieving Control on Long-Term Biologic Therapy
July 3rd 2025

Adjusting Asthma Management After Achieving Control on Long-Term Biologic Therapy

Yvonne Riley-Poku, PharmD
X-ray image of kidneys with CKD -- Image credit: Crystal light | stock.adobe.com
July 2nd 2025

FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD-Related Hyperphosphatemia

Gillian McGovern, Associate Editor